Ocular drug delivery system: A reference to natural polymers

Expert Opinion on Drug Delivery

Volumn 9, Issue 7, 2012, Pages 837-861

  Pahuja, Priyanka ^a   Arora, Sandeep ^a   Pawar, Pravin ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

formulation approaches; natural polymers; ocular bioavailability; ocular drug delivery

Indexed keywords

ALBUMIN; ALGAROBA; ALGINIC ACID; ARABINOGALACTAN; ATROPINE; BLETILLA STRIATA POLYSACCHARIDE; CARBOMER; CARRAGEENAN; CHITOSAN; CHLORAMPHENICOL; CIPROFLOXACIN; COLLAGEN; EYE DROPS; FLUOROURACIL; GELATIN; GELLAN; GUAR GUM; GUM CORDIA; HYALURONIC ACID; INDOMETACIN; LIPOSOME; PILOCARPINE; POLOXAMER; POLYMER; POLYSACCHARIDE; POVIDONE; STARCH; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHAN; XYLOGLUCAN;

AQUEOUS HUMOR; BIOCOMPATIBILITY; BIODEGRADATION; COLLOID; CONJUNCTIVA EPITHELIUM; CONTACT LENS; CORNEA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; EX VIVO STUDY; HUMAN; HYDROGEL; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR DRUG ADMINISTRATION; IONTOPHORESIS; LACRIMATION; LIPOPHILICITY; MICELLIZATION; MUCOADHESION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PARTITION COEFFICIENT; PH; REVIEW; TABLET; VISCOSITY; VITREOUS BODY; ZETA POTENTIAL;

ADMINISTRATION, TOPICAL; CARRAGEENAN; DOSAGE FORMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EYE DISEASES; GALACTANS; GENETIC THERAPY; HUMANS; PLANT GUMS; POLYMERS; POLYSACCHARIDES, BACTERIAL;

EID: 84862728671     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.690733     Document Type: Review

References (256)

1. Mitra AK. editor. Ophthalmic drug delivery systems. 2nd edition. Marcel Dekker, Inc; New York, USA: 2003. p. 1-15
2. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res 2009;26:1197-216
3. McClellan KA. Mucosal defense of the outer eye. Surv Ophthalmol 1997;42:233-46
4. Sieg JW, Robinson JR. Mechanistic studies on transcorneal permeation of pilocarpine. J Pharm Sci 1976;65:1816-22 (Pubitemid 8001799)
5. Henderer JD, Raprano CJ. Ocular pharmacology. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw-Hill; New York, USA: 2005. p: 1707-37
6. Lang JC, Roehrs RE, Rodeheavers DP, et al. Design and evaluation of ophthalmic pharmaceutical products. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics. 4th edition. Marcel Dekker, Inc; New York, USA: 2002. p. 418-81
7. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000;27:558-62 (Pubitemid 30418006)
8. Lang JC, Roehrs RE, Jani R. Ophthalmic preparations. In: Gerbino PP, editor. Remington: the science and practice of pharmacy. 21st edition. Lippincott Williams & Wilkins; Philadelphia, USA: 2005. p. 850-70
9. Keister JC, Cooper ER, Missel PJ, et al. Limits on optimizing ocular drug delivery. J Pharm Sci 1991;80:50-3
10. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol 1990;74:477-80 (Pubitemid 20269092)
11. Mishima S, Gasset A, Klyce SD Jr, Baum JL. Determination of tear volume and tear flow. Invest Ophthalmol 1966;5:264-76
12. Schoenwald RD, Boltralik JJ. A bioavailability comparison in rabbits of two steroids formulated as high viscosity gels and reference aqueous preparations. Invest Ophthalmol Vis Sci 1979;18:61-6 (Pubitemid 9051108)
13. Benedetto DA, Shah DO, Kaufman HE. The instilled fluid dynamics and surface chemistry of polymers in the pre ocular tear film. Invest Ophthalmol 1975;14:887-902
14. Pfister RR, Burstein N. The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest Ophthalmol 1976;15:246-59
15. Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res 1989;49:1-12 (Pubitemid 19190148)
16. Lidgate DM, Fu RC, Fleitman JS. Corneal permeability of ketorolac tromethamine when formulated with tobramycin. Drug Dev Ind Pharm 1989;15:1779-95 (Pubitemid 19194669)
17. Schrage NF, Schlossmacher B, Aschenbernner W, Langefeld S. Phosphate buffer in alkali eye burns as an inducer of experimental corneal calcification. Burns 2001;27:459-64 (Pubitemid 32655018)
18. Schrage NF, Frentz M, Reim M. Changing the composition of buffered eye-drops prevents undesired side effects. Br J Ophthalmol 2010;94:1519-22
19. Hardberger R, Hanna C, Boyd CM. Effects of drug vehicles on ocular contact time. Arch Ophthalmol 1975;93:42-5
20. Shchipanova AI, Maichuk IuF, Nikolaeva IS, Pershin GN. Pharmacokinetics and antiviral activity of riodoksol in an ointment and in ophthalmic drug films in ocular herpes. Farmakol Toksikol 1981;44:439-42 (Pubitemid 11041267)
21. Greaves JL, Wilson CG, Birmingham AT. Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects. Br J Clin Pharmacol 1993;35:188-92 (Pubitemid 23055322)
22. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001;73:205-11 (Pubitemid 32539249)
23. Gupta H, Velpandian T, Jain S. Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery. J Drug Target 2010;18:499-505
24. Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv 2003;10:185-91 (Pubitemid 36993370)
25. Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 2000;69:379-88
26. Ma WD, Xu H, Nie SF, Pan WS. Temperature-responsive, Pluronic-g-poly (acrylic acid) copolymers in situ gels for ophthalmic drug delivery: rheology, in vitro drug release, and in vivo resident property. Drug Dev Ind Pharm 2008;34:258-66 (Pubitemid 351431197)
27. Bensinger R, Shin DH, Kass MA, et al. Pilocarpine ocular inserts. Invest Ophthalmol 1976;15:1008-10 (Pubitemid 8039562)
28. Sultana Y, Aqil M, Ali A. Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation. Acta Pharm 2005;55:305-14 (Pubitemid 41495274)
29. Hsiue GH, Guu JA, Cheng CC. Poly(2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine. Biomaterials 2001;22:1763-9
30. Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. Drug Dev Ind Pharm 2003;29:215-21 (Pubitemid 36292944)
31. Di Colo G, Burgalassi S, Chetoni P, et al. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Int J Pharm 2001;215:101-11 (Pubitemid 32206608)
32. Deshpande PB, Dandagi P, Udupa N, et al. Controlled release polymeric ocular delivery of acyclovir. Pharm Dev Technol 2010;15:369-78
33. Sedlacek J. Possibility of application of eye drugs with the aid of gel-contact lenses. Cesk Oftalmol 1965;21:509-12
34. Singh K, Nair AB, Kumar A, Kumria R. Novel approaches in formulation and drug delivery using contact lenses. J Basic Clin Pharm 2011;2:87-101
35. Hillman JS. Management of acute glaucoma with Pilocarpine-soaked hydrophilic lens. Br J Ophthalmol 1974;58:674-9
36. Karlgard CC, Wong NS, Jones LW, Moresoli C. In vitro uptake and release studies of ocular pharmaceutical agents by silicon-containing and p-HEMA hydrogel contact lens materials. Int J Pharm 2003;257:141-51 (Pubitemid 36507040)
37. Costa VP, Mara EM, Braga A, et al. Development of therapeutic contact lenses using a supercritical solvent impregnation method. J Supercrit Fluids 2010;52:306-16
38. Alvarez-Lorenzo C, Yanez F, Barreiro-Iglesias R, Concheiro A. Imprinted soft contact lenses as norfloxacin delivery systems. J Control Release 2006;113:236-44 (Pubitemid 43963192)
39. Hiratani H, Fujiwara A, Tamiya Y, et al. Ocular release of timolol from molecularly imprinted soft contact lenses. Biomaterials 2005;26:1293-8 (Pubitemid 39314503)
40. Baer E, Cassidy JJ, Hiltner A. Hierarchial structure of collagen composite system: lessons from biology. Pure Appl Chem 1991;63:961-73
41. Komai Y, Ushiki T. The three-dimensional organization of collagen fibrils in the human cornea and sclera. Invest Ophthalmol Vis Sci 1991;32:2244-58
42. Shaker GJ, Ueda S, LoCascio JA, Aquavella JV. Effect of a collagen shield on cat corneal epithelial wound healing. Invest Ophthalmol Vis Sci 1989;30:1565-8 (Pubitemid 19185959)
43. Palmer RM, McDonald MB. A corneal lens/shield system to promote postoperative corneal epithelial healing. J Cataract Refract Surg 1995;21:125-6
44. Erwin LR. Glucan/collagen therapeutic eye shields. US4946450; 1990
45. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 1996;85:530-6 (Pubitemid 26153217)
46. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol 1996;48:1147-52 (Pubitemid 126449485)
47. Zimmer AK, Zerbeb H, Kreuter J. Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye I. In vitro and in vivo characterization. J Control Release 1994;32:57-70
48. Zimmer AK, Chetoni P, Saettone MF, et al. Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye II. Co-administration with bioadhesive and viscous polymers. J Control Release 1995;33:31-46
49. Bin Choy Y, Park JH, Prausnitz MR. Mucoadhesive microparticles engineered for ophthalmic drug delivery. J Phys Chem Solids 2008;69:1533-6
50. Smolin G, Okumoto M, Feiler S, Condon D. Idoxuridine-liposome therapy for herpes simplex keratitis. Am J Ophthalmol 1981;91:220-5 (Pubitemid 11184484)
51. Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci 1982;22:220-7 (Pubitemid 12123834)
52. Taniguchi K, Itakura K, Yamazawa N, et al. Efficacy of a liposome preparation of anti-inflammatory steroid as an ocular drug-delivery system. J Pharmacobiodyn 1988;11:39-46 (Pubitemid 18062172)
53. Schaeffer HE, Breitfeller JM, Krohn DL. Lectin-mediated attachment of liposomes to cornea: influence on transcorneal drug flux. Invest Ophthalmol Vis Sci 1982;23:530-3 (Pubitemid 12000569)
54. Kaufman HE, Steinemann TL, Lehman E, et al. Collagen-based drug delivery and artificial tears. J Ocul Pharmacol 1994;10:17-27 (Pubitemid 24119427)
55. Liu Y, Sun K, Yao W, et al. Corneal penetration of PAMAM dendrimers-coated puerarin liposomes. Zhongguo Zhong Yao Za Zhi 2010;35:30-4
56. Aggarwal D, Garg A, Kaur IP. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J Pharm Pharmacol 2004;56:1509-17 (Pubitemid 39601991)
57. Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech 2008;9:740-7
58. Vyas SP, Mysore N, Jaitely V, Venkatesan N. Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie 1998;53:466-9 (Pubitemid 28338283)
59. Abdelkader H, Ismail S, Kamal A, Alany RG. Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J Pharm Sci 2011;100:1833-46
60. Weyenberg W, Vermeire A, Remon JP, Ludwig A. Characterization and in vivo evaluation of ocular bioadhesive minitablets compressed at different forces. J Control Release 2003;89:329-40 (Pubitemid 36507025)
61. Weyenberg W, Bozdag S, Foreman P, et al. Characterization and in vivo evaluation of ocular minitablets prepared with different bioadhesive Carbopol-starch components. Eur J Pharm Biopharm 2006;62:202-9 (Pubitemid 43143273)
62. Pijls RT, Hanssen HH, Nuijts RM, Koole LH. Flexible coils with a drug-releasing hydrophilic coating: a new platform for controlled delivery of drugs to the eye? Biomed Mater Eng 2004;14:383-93 (Pubitemid 40916711)
63. Pijls RT, Sonderkamp T, Daube GW, et al. Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm 2005;59:283-8 (Pubitemid 40127585)
64. Pijls RT, Cruysberg LP, Nuijts RM, et al. Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm 2007;341:152-61 (Pubitemid 47088118)
65. Dias AA, Koole LH, Pijls RT. Coiled wire for the controlled release of drugs to the eye. US20090143747A1; 2009
66. Fishman PH, Jay WM, Rissing JP, et al. Iontophoresis of gentamicin into aphakic rabbit eyes. Sustained vitreal levels. Invest Ophthalmol Vis Sci 1984;25:343-5 (Pubitemid 14164783)
67. Hobden JA, Rootman DS, O'Callaghan RJ, Hill JM. Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas. Antimicrob Agents Chemother 1988;32:978-81
68. Hobden JA, O'Callaghan RJ, Hill JM, et al. Tobramycin iontophoresis into corneas infected with drug-resistant Pseudomonas aeruginosa. Curr Eye Res 1989;8:1163-9 (Pubitemid 20002325)
69. Grossman RE, Chu DF, Lee DA. Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis. Invest Ophthalmol Vis Sci 1990;31:909-16 (Pubitemid 20186102)
70. Hobden JA, Reidy JJ, O'Callaghan RJ, et al. Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. Invest Ophthalmol Vis Sci 1990;31:1940-4 (Pubitemid 20355802)
71. Pescina S, Ferrari G, Govoni P, et al. In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application. J Pharm Pharmacol 2010;62:1189-94
72. Molokhia SA, Jeong EK, Higuchi WI, Li SK. Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp Eye Res 2009;88:418-25
73. Vollmer DL, Szlek MA, Kolb K, et al. In vivo transscleral iontophoresis of amikacin to rabbit eyes. J Ocul Pharmacol Ther 2002;18:549-58 (Pubitemid 36020256)
74. Singh RP, Mathews ME, Kaufman M, Riga A. Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal tissues using macroesis. Br J Ophthalmol 2010;94:170-3
75. Kumar MN, Muzzarelli RA, Muzzarelli C, et al. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004;104:6017-84 (Pubitemid 40025733)
76. Seda Tigli R, Karakecili A, Gumusderelioglu M. In vitro characterization of chitosan scaffolds: influence of composition and deacetylation degree. J Mater Sci Mater Med 2007;18:1665-74 (Pubitemid 47224922)
77. Felt O, Furrer P, Mayer JM, et al. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm 1990;180:185-93
78. He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm 1998;166:75-88 (Pubitemid 28239741)
79. Ikeda S, Kumagai H, Sakiyama T, et al. Method for analyzing pH-sensitive swelling of amphoteric hydrogels: application to a polyelectrolyte complex gel prepared from xanthan and chitosan. Biosci Biotech Biochem 1995;59:1422-7
80. Di Colo G, Zambito Y, Burgalassi S, et al. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int J Pharm 2004;273:37-44 (Pubitemid 38317038)
81. Di Colo G, Zambito Y, Burgalassi S, et al. Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly (ethylene oxide). Int J Pharm 2002;248:115-22 (Pubitemid 35341415)
82. Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm 2008;348:175-8 (Pubitemid 350266247)
83. Zambito Y, Zaino C, Di Colo G. Effects of N-trimethylchitosan on transcellular and paracellular transcorneal drug transport. Eur J Pharm Biopharm 2006;64:16-25 (Pubitemid 44142234)
84. Contreras-Ruiz L, de la Fuente M, Garcia-Vazquez C, et al. Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles. Cornea 2010;29:550-8
85. Braga ME, Pato MT, Silva HS, et al. Supercritical solvent impregnation of ophthalmic drugs on chitosan derivatives. J Supercritical Fluids 2008;44:245-57 (Pubitemid 351199816)
86. Cao Y, Zhang C, Shen W, et al. Poly (N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J Control Release 2007;120:186-94 (Pubitemid 47058641)
87. Gratieri T, Gelfuso GM, Rocha EM, et al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010;75:186-93
88. Gupta S, Vyas SP. Carbopol/Chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. Sci Pharm 2010;78:959-76
89. Ur-Rehman T, Tavelin S, Grobner G. Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int J Pharm 2011;409:19-29
90. Gorle AP, Gattani SG. Design and evaluation of polymeric ocular drug delivery system. Chem Pharm Bull (Tokyo) 2009;57:914-19
91. Abdelbary G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm Dev Technol 2011;16:44-56
92. Zhang J, Wang S. Topical use of Coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. Int J Pharm 2009;372:66-75
93. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001;224:159-68 (Pubitemid 32706495)
94. Yuan XB, Li H, Yuan YB. Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr Polym 2006;65:337-45 (Pubitemid 44160627)
95. Yuan XB, Yuan YB, Jiang W, et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 2008;349:241-8
96. Enriquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 2006;47:1416-25 (Pubitemid 46780748)
97. Nagarwal RC, Singh PN, Kant S, et al. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in vitro and in vivo study. Chem Pharm Bull (Tokyo) 2011;59:272-8
98. Sandri G, Bonferoni MC, Gokce EH, et al. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Microencapsul 2010;27:735-46
99. Refai H, Tag R. Development and characterization of sponge-like acyclovir ocular minitablets. Drug Deliv 2011;18:38-45
100. Lin HR, Yu SP, Kuo CJ, et al. Pilocarpine-loaded chitosan-PAA nanosuspension for ophthalmic delivery. J Biomater Sci Polym Ed 2007;18:205-21
101. Wu XG, Xin M, Yang LN, Shi WY. The biological characteristics and pharmacodynamics of a mycophenolate mofetil nanosuspension ophthalmic delivery system in rabbits. J Pharm Sci 2011;100:1350-61
102. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 2005;290:155-9 (Pubitemid 40139055)
103. Kaur IP, Aggarwal D, Singh H, Kakkar S. Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. Graefes Arch Clin Exp Ophthalmol 2010;248:1467-72
104. Yamaguchi M, Ueda K, Isowaki A, et al. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Biol Pharm Bull 2009;32:1266-71
105. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011;403:185-91
106. Kogan G, Soltes L, Stern R, Gemeiner P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett 2007;29:17-25 (Pubitemid 44950153)
107. Stoolmiller AC, Dorfman A. The biosynthesis of hyaluronic acid by Streptococcus. J Biol Chem 1969;244:236-46
108. Alpar JJ. The role of 1% sodium hyaluronate in treating vitreous incarceration with the neodymium: YAG laser in patients with corneal decompensation. J Cataract Refract Surg 1986;12:502-6 (Pubitemid 17189712)
109. Pape LG, Balazs EA. The use of sodium hyaluronate (Healon) in human anterior segment surgery. Ophthalmology 1980;87:699-705 (Pubitemid 10080279)
110. Bresciani C, Lebuisson DA, Eveillard M, et al. Dynamic viscosity and corneal endothelial protection with Healonid, Healon GV, Provisc and Viscoat during phacoemulsification. J Fr Ophtalmol 1996;19:39-50 (Pubitemid 26064625)
111. Kanski JJ. Intravitreal hyaluronic acid injection. A long-term clinical evaluation. Br J Ophthalmol 1975;59:255-6
112. Pruett RC, Schepens CL, Swann DA. Hyaluronic acid vitreous substitute. A six-year clinical evaluation. Arch Ophthalmol 1979;97:2325-30 (Pubitemid 10190523)
113. Koster R, Stilma JS. Healon as intravitreal substitute in retinal detachment surgery in 40 patients. Doc Ophthalmol 1986;64:13-17 (Pubitemid 17015150)
114. Camber O, Edman P. Sodium hyaluronate as an ophthalmic vehicle: some factors governing its effect on the ocular absorption of pilocarpine. Curr Eye Res 1989;8:563-7 (Pubitemid 19160718)
115. Nesseem DI. Ophthalmic delivery of sparfloxacin from in situ gel formulation for treatment of experimentally induced bacterial keratitis. Drug Test Anal 2011;3:106-15
116. Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Curr Eye Res 1987;6:779-84 (Pubitemid 17109903)
117. Xu Y, Song JZ, Pang GR, et al. Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits. Zhonghua Yan Ke Za Zhi 2004;40:87-9
118. Bernatchez SF, Tabatabay C, Gurny R. Sodium hyaluronate 0.25% used as a vehicle increases the bioavailability of topically administered gentamicin. Graefes Arch Clin Exp Ophthalmol 1993;231:157-61 (Pubitemid 23088022)
119. Mengher LS, Pandher KS, Bron AJ, Davey CC. Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes. Br J Ophthalmol 1986;70:442-7 (Pubitemid 16114892)
120. Ludwig A, Van Ooteghem M. Evaluation of sodium hyaluronate as viscous vehicle for eye drops. J Pharm Belg 1989;44:391-7 (Pubitemid 20124182)
121. Wysenbeek YS, Loya N, Ben Sira I, et al. The effect of sodium hyaluronate on the corneal epithelium. An ultrastructural study. Invest Ophthalmol Vis Sci 1988;29:194-9 (Pubitemid 18057566)
122. Hamano T, Horimoto K, Lee M, Komemushi S. Evaluation of the effect of the sodium hyaluronate ophthalmic solution on tear film stability--non-contact specular microscopic evaluation. Nippon Ganka Gakkai Zasshi 1993;97:928-32 (Pubitemid 23280931)
123. Johnson ME, Murphy PJ, Boulton M. Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment. Optom Vis Sci 2008;8:750-7
124. Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002;86:181-4 (Pubitemid 34127543)
125. Vogel R, Crockett RS, Oden N, et al. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (Vismed, Rejena). Am J Ophthalmol 2010;149:594-601
126. Su WY, Chen KH, Chen YC, et al. An Injectable oxidated hyaluronic acid/adipic acid dihydrazide hydrogel as a Vitreous Substitute. J Biomater Sci Polym Ed 2011;22:1777-97
127. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target 2010;18:292-302
128. Saettone MF, Chetoni P, Torracca MT, et al. Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J Pharm 1989;51:203-12 (Pubitemid 19117685)
129. Sandri G, Rossi S, Ferrari F, et al. Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcine buccal and vaginal tissue, Caco-2 cell lines, and rat jejunum. J Pharm Pharmacol 2004;56:1083-90 (Pubitemid 39207188)
130. de la Fuente M, Seijo B, Alonso MJ. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther 2008;15:668-76 (Pubitemid 351524521)
131. Contreras-Ruiz L, de la Fuente M, Parraga JE, et al. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis 2011;17:279-90
132. Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm 2010;7:576-85
133. Rowe RC, Sheskey PJ, Owen SC. editors. Handbook of pharmaceutical excipients. 5th edition. Pharmaceutical Press; London, UK: 2006
134. Demailly P, Allaire C, Trinquand C. Ocular hypotensive efficacy and safety of once daily carteolol alginate. Br J Ophthalmol 2001;85:921-4 (Pubitemid 32706162)
135. Sechoy O, Tissie G, Sebastian C, et al. A new long acting ophthalmic formulation of carteolol containing alginic acid. Int J Pharm 2000;207:109-16
136. Kesavan K, Nath G, Jayanta K, Pandit JK. Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity. Sci Pharm 2010;78:941-57
137. Samanta A, Ghosal SK. Prolonged delivery of ciprofloxacin hydrochloride from hydrophilic ocular inserts. Acta Pol Pharm 2004;61:343-9 (Pubitemid 40188846)
138. Gilhotra RM, Mishra DN. Alginate-chitosan film for ocular drug delivery: effect of surface cross-linking on film properties and characterization. Pharmazie 2008;63:576-9
139. Koelwel C, Rothschenk S, Fuchs-Koelwel B, et al. Alginate inserts loaded with epidermal growth factor for the treatment of Keratoconjunctivitis sicca. Pharm Dev Technol 2008;13:221-31 (Pubitemid 351882241)
140. Gilhotra RM, Nagpal K, Mishra DN. Azithromycin novel drug delivery system for ocular application. Int J Pharm Invest 2011;1:22-8
141. Liu W, Griffith M, Li F. Alginate microsphere-collagen composite hydrogel for ocular drug delivery and implantation. J Mater Sci Mater Med 2008;19:3365-71
142. McHugh DJ. Production, properties and uses of alginates. In: Production and Utilization of Products from Commercial Seaweeds. FAO Fisheries Technical Paper 288. Food and Agriculture Organization of The United Nations; Rome: 1987. Available from: http://www.fao.org/docrep/X5822E/x5822e04.htm. [Last accessed 7 February 2012]
143. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release 1997;44:201-8 (Pubitemid 27039116)
144. Liu Z, Li J, Nie S, et al. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 2006;315:12-17 (Pubitemid 43674115)
145. Abraham S, Furtado S, Bharath S, et al. Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system. Pak J Pharm Sci 2009;22:175-9
146. Hassan MA. A long acting ophthalmic gel formulations of atenolol. Drug Dev Ind Pharm 2007;33:1192-8 (Pubitemid 350208741)
147. Ahuja N, Saini V, Bishnoi VK, et al. Formulation and evaluation of diclofenac sodium gel by using natural polymer. Rasayan J Chem 2008;1:564-6
148. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008;68:513-25 (Pubitemid 351318222)
149. Gilhotra RM, Gilhotra N, Mishra DN. A hydrogel--forming bioadhesive ocular minitablet for the management of microbial Keratitis. Asian J Pharm Sci 2010;5:19-25
150. Kang KS, Veeder GT, Mirrasoul PJ, et al. Agar-like polysaccharide produced by a pseudomonas species: production and basic properties. Appl Environ Microbiol 1982;43:1086-91 (Pubitemid 12067113)
151. Lobas D, Schumpe S, Deckwer WD. The production of gellan exopolysaccharide with Sphingomonas paucimobilis E2 (DSM 6314). Appl Microbiol Biotechnol 1992;37:411-15
152. Shungu D, Valiant M, Tutlane V, et al. Gelrite® as an agar substitute in bacteriological media. Appl Environ Microbiol 1983;46:840-5 (Pubitemid 14236275)
153. Carlfors J, Edsman K, Petersson R, Jornving K. Rheological evaluation of Gelrite® in situ gels for ophthalmic use. Eur J Pharm Sci 1998;6:113-19 (Pubitemid 28164281)
154. Edsman K, Carlfors J, Harju K. Rheological evaluation and ocular contact time of some carbomer gels for ophthalmic use. Int J Pharm 1996;137:233-41 (Pubitemid 26226075)
155. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 1998;6:105-12 (Pubitemid 28164280)
156. Greaves JL, Wilson CG, Rozier A, et al. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res 1990;9:415-20 (Pubitemid 20203500)
157. Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite®: A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm 1989;57:163-8 (Pubitemid 20011840)
158. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin. Acta Pharm 2003;53:251-61 (Pubitemid 38083940)
159. El-Kamel A, Al-Dosari H, Al-Jenoobi F. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv 2006;13:55-9 (Pubitemid 43087621)
160. Sultana Y, Aqil M, Ali A. Ion-Activated, Gelrite® based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv 2006;13:215-19
161. Singh SR, Carreiro ST, Chu J, et al. L-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations. J Pharm Pharmacol 2009;61:733-42
162. Liu Y, Liu J, Zhang X, et al. In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery. AAPS PharmSciTech 2010;11:610-20
163. Shen JQ, Gan Y, Gan L, et al. Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil. Yao Xue Xue Bao 2010;45:120-5
164. Balasubramaniam J, Kumar MT, Pandit JK, Kant S. Gellan-based scleral implants of indomethacin: in vitro and in vivo evaluation. Drug Deliv 2004;11:371-9 (Pubitemid 39578596)
165. Suri S, Banerjee R. In vitro evaluation of in situ gels as short term vitreous substitutes. J Biomed Mater Res A 2006;79:650-64 (Pubitemid 44845180)
166. Lodish H, Berk A, Zipursky SL, et al. editors. Molecular cell biology. 4th edition. Freeman WH; New York: 2000. Available from: http://www.ncbi.nlm. nih.gov/books/NBK21582/. [Last accessed 7 February 2012]
167. Gerbino PP. editor. Remington: the science and practice of pharmacy. 21st edition. Lippincott Williams & Wilkins; Philadelphia, USA: 2005. p. 1318-49
168. Willoughby CE, Batterbury M, Kaye SB. Collagen corneal shields. Surv Ophthalmol 2002;47:174-82 (Pubitemid 34252976)
169. Liang FQ, Viola RS, Cerro MD, Aquavella JV. Noncross-linked collagen discs and cross-linked collagen shields in the delivery of gentamicin to rabbits eyes. Invest Ophthalmol Vis Sci 1992;33:2194-8
170. Phinney RB, Schwartz SD, Lee DA, Mondino BJ. Collagen-shield delivery of gentamicin and vancomycin. Arch Ophthalmol 1988;106:1599-604
171. Huang ZP, Wu JA. An experimental study of gentamycin delivery into cornea and aqueous humor from the collagen corneal shield. Zhonghua Yan Ke Za Zhi 1992;28:170-2
172. Murray TG, Stern WH, Chin DH, MacGowan-Smith EA. Collagen shield heparin delivery for prevention of postoperative fibrin. Arch Ophthalmol 1990;108:104-6 (Pubitemid 20031421)
173. Wang JM, Chu RY, Li YT. Cephradine delivery into the eye with domestic collagen shield. Zhonghua Yan Ke Za Zhi 1994;30:131-3
174. Dorigo MT, De Natale R, Miglioli PA. Collagen shields delivery of netilmicin: a study of ocular pharmacokinetics. Chemotherapy 1995;41:1-4 (Pubitemid 24375186)
175. Finkelstein I, Trope GE, Heathcote JG, et al. Further evaluation of
176. Gebhardt BM, Kaufman HE. Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine. J Ocul Pharmacol Ther 1995;11:319-27
177. Miyata T, Rubin AL, Stenzel KH, Dunn MW. Collagen drug delivery device. US4164559; 1979
178. Punch PI, Slatter DH, Costa ND, Edwards ME. Ocular inserts for application of drugs to bovine eyes-in vitro studies on gentamicin release from collagen inserts. Aust Vet J 1985;62:79-82
179. Vasantha V, Sehgal PK, Rao KP. Collagen ophthalmic inserts for pilocarpine drug delivery system. Int J Pharm 1988;47:95-102
180. Cao N, Fu Y, He J. Mechanical properties of gelatin films cross-linked, respectively, by ferulic acid and tannin acid. Food Hydrocolloids 2007;21:575-84 (Pubitemid 46110923)
181. Available from: http://www.pfizer.com/files/products/uspi-gelfilm.pdf [Last accessed 6 February 2012]
182. Available from: http://www.bdipharma.com/Package%20Insert/Pfizer/Gelfoam. pdf [Last accessed 6 February 2012]
183. Pinsuwan S, Myrdal PB, Yalkowsky SH. Systemic delivery of melanotan II through the ocular route in rabbits. J Pharm Sci 1997;86:396-7 (Pubitemid 27372316)
184. Simamora P, Lee YC, Yalkowsky SH. Ocular device for the controlled systemic delivery of insulin. J Pharm Sci 1996;85:1128-30 (Pubitemid 26338931)
185. Lee YC, Yalkowsky SH. Ocular devices for the controlled systemic delivery of insulin: in vitro and in vivo dissolution. Int J Pharm 1999;181:71-7 (Pubitemid 29199889)
186. Nadkarni SR, Yalkowsky SH. Controlled delivery of pilocarpine. 1. In vitro characterization of Gelfoam matrices. Pharm Res 1993;10:109-12 (Pubitemid 23020846)
187. Simamora P, Nadkarni SR, Lee YC, Yalkowsky SH. Controlled delivery of pilocarpine. 2. In-vivo evaluation of Gelfoam® device. Int J Pharm 1998;170:209-14 (Pubitemid 28473288)
188. Lee YC, Millard JW, Negvesky GJ, et al. Formulation and in vivo evaluation of ocular insert containing phenylephrine and tropicamide. Int J Pharm 1999;182:121-6
189. Mundada AS, Shrikhande BK. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Dev Ind Pharm 2006;32:443-8
190. Mundada AS, Shrikhande BK. Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 2008;33:469-75 (Pubitemid 351998850)
191. Jain D, Carvalho E, Banthia AK, Banerjee R. Development of polyvinyl alcohol-gelatin membranes for antibiotic delivery in the eye. Drug Dev Ind Pharm 2011;37:167-77
192. Mathurm M, Gilhotra RM. Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E2-induced ocular inflammation. Drug Deliv 2011;18:54-64
193. Sandri G, Bonferoni MC, Chetoni P, et al. Ophthalmic delivery systems based on drug-polymer-polymer ionic interaction: in vitro and in vivo characterization. Eur J Pharm Biopharm 2006;62:59-69 (Pubitemid 41736026)
194. Shimmura S, Ueno R, Matsumoto Y, et al. Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol 2003;87:1279-83 (Pubitemid 37193922)
195. Rathod S, Deshpande SG. Albumin microspheres as an ocular delivery system for pilocarpine nitrate. Indian J Pharm Sci 2008;70:193-7 (Pubitemid 351920195)
196. Das SK, Banerjee R, Bellare J. Aspirin loaded albumin nanoparticles by coacervation: implications in drug delivery. Trends Biomater Artif Organs 2005;18:203-12
197. Zimmer AK, Maincent P, Thouvenot P, Kreuter J. Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles. Int J Pharm 1994;110:211-22 (Pubitemid 24274228)
198. Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci 2001;12:251-9
199. McCormick C, Caballero A, Tang A, et al. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis. Curr Med Res Opin 2008;24:1569-75 (Pubitemid 351929055)
200. Ceulemans J, Vinckier I, Ludwig A. The use of xanthan gum in an ophthalmic liquid dosage form: rheological characterization of the interaction with mucin. J Pharm Sci 2002;91:1117-27 (Pubitemid 34640936)
201. Shastri DH, Prajapati ST, Patel LD. Design and development of thermoreversible ophthalmic in situ hydrogel of moxifloxacin HCl. Curr Drug Deliv 2010;7:238-43
202. Meseguer G, Buri P, Plazonnet B, et al. Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 1996;12:481-8 (Pubitemid 26405752)
203. Chastaing G, Plazonnet B, Rozier A. Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum. WO9817249; 1998
204. Hiremath SSP, Dasankoppa FS, Nadaf A, et al. Formulation and evaluation of a novel in situ gum based ophthalmic drug delivery system of Linezolid. Sci Pharm 2008;76:515-32
205. Gaonkar GV, Gude RS. Formulation development and evaluation of long acting ophthalmic in-situ gelling systems of ketorolac tromethamine and ofloxacin: a research. Int J Drug Formul Res 2010;1:185-200
206. Schenker HI, Silver LH. Long-term intraocular pressure-lowering efficacy and safety of timolol maleate gel-forming solution 0.5% compared with Timoptic XE 0.5% in a 12-month study. Am J Ophthalmol 2000;130:145-50
207. Thrimawithana TR, Young S, Alany RG. Evaluation of carrageenan and methyl-cellulose binary systems for ophthalmic controlled delivery of macromolecules. Available from: http://www.aapsj.org/abstracts/AM-2010/W4083.pdf [Last accessed 6 Februray 2012]
208. Bonferoni MC, Chetoni P, Giunchedi P, et al. Carrageenan-gelatin mucoadhesive systems for ion-exchange based ophthalmic delivery: in vitro and preliminary in vivo studies. Eur J Pharm Biopharm 2004;57:465-72 (Pubitemid 38490563)
209. Stiles J, Guptill-Yoran L, Moore GE, Pogranichniy RM. Effects of lambda-carrageenan on in vitro replication of feline herpes virus and on experimentally induced herpetic conjunctivitis in cats. Invest Ophthalmol Vis Sci 2008;49:1496-501
210. Swinkels JJM. Composition and properties of commercial native starches. Starch Starke 1985;37:1-5
211. Weyenberg W, Vermeire A, D'Haese E, et al. Effect of different sterilisation methods on the properties of bioadhesive powders and ocular minitablets, and clinical evaluation. Eur J Pharm Sci 2004;23:77-87 (Pubitemid 39486000)
212. Weyenberg W, Vermeire A, Dhondt MM, et al. Ocular bioerodible minitablets as strategy for the management of microbial keratitis. Invest Ophthalmol Vis Sci 2004;45:3229-33 (Pubitemid 39121860)
213. Bozdag S, Weyenberg W, Adriaens E, et al. In vitro evaluation of gentamicin- and vancomycin-containing minitablets as a replacement for fortified eye drops. Drug Dev Ind Pharm 2010;36:1259-70
214. Khullar P, Khar RK, Agarwal SP. Evaluation of guar gum in the preparation of sustained-release matrix tablets. Drug Dev Ind Pharm 1998;24:1095-9 (Pubitemid 28460250)
215. Krishnaiah YS, Satyanarayana V, Dinesh Kumar B, Karthikeyan RS. In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur J Pharm Sci 2002;16:185-92 (Pubitemid 34786453)
216. Available from: http://www.systane.com/ [Last accessed 7 February 2012]
217. Cheng Y, Brown KM, Prud'homme RK. Characterization and intermolecular interactions of hydroxypropyl guar solutions. Biomacromolecules 2002;3:456-61 (Pubitemid 34567446)
218. Christensen MT, Cohen S, Rinehart J, et al. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res 2004;28:55-62 (Pubitemid 38161174)
219. Ubels JL, Clousing DP, Van Haitsma TA, et al. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent. Curr Eye Res 2004;28:437-44 (Pubitemid 39090328)
220. Saettone MF, Burglassi S, Glannaccini B, et al. Ophthalmic solutions viscosified with tamarind gum polysaacharide. US6056950; 2000
221. Miyazaki S, Suzuki S, Kawasaki N, et al. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 2001;229:29-36 (Pubitemid 32972078)
222. Burgalassi S, Panichi L, Chetoni P, et al. Development of simple dry eye model in the albino rabbit and evaluation of some tear substitutes. Ophthalmic Res 1999;31:229-35 (Pubitemid 29219120)
223. Prete AD, Sanso M. Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid. US20100279981A1; 2010
224. Raimondi L, Sgromo L, Banchelli G, et al. A new viscosity enhancer for ophthalmic preparations devoid of toxicity for human conjunctival cells. J Toxicol Cutan Ocul Toxicol 2000;19:31-42 (Pubitemid 30123879)
225. Rolando M, Valente C. Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: results of a clinical study. BMC Ophthalmol 2007;29:7-5
226. Uccello-Barretta G, Nazzi S, Balzano F, Sanso M. A nuclear magnetic resonance approach to the comparison of mucoadhesive properties of polysaccharides for ophthalmic uses. Int J Pharm 2011;406:78-83
227. Ghelardi E, Tavanti A, Davini P, et al. A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. Antimicrob Agents Chemother 2004;48:3396-401 (Pubitemid 39129336)
228. Uccello-Barretta G, Nazzi S, Zambito Y, et al. Synergistic interaction between TS-polysaccharide and hyaluronic acid: implications in the formulation of eye drops. Int J Pharm 2010;395:122-31
229. Burgalassi S, Chetoni P, Panichi L, et al. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J Ocular Pharmacol Ther 2000;16:497-509
230. Ghelardi E, Tavanti A, Celandroni F, et al. Effect of a novel mucoadhesive polysaccharide obtained from tamarind seeds on the intraocular penetration of gentamicin and ofloxacin in rabbits. J Antimicrob Chemother 2000;46:831-4
231. Burgalassi S, Cappello B, Chetoni P, et al. Rufloxacin eyedrops: effect of different formulations on ocular pharmacokinetics in rabbits. Eur J Ophthalmol 2006;16:311-17 (Pubitemid 43880056)
232. Di Colo G, Zambito Y, Zaino C, Sanso M. Selected polysaccharides at comparison for their mucoadhesiveness and effect on precorneal residence of different drugs in the rabbit model. Drug Dev Ind Pharm 2009;35:941-9
233. Larch Arabinogalactan. Monograph, alternative medicine review. Thorne Res 2000;5:463-6
234. Prescott JH, Enriquez P, Jung C, et al. Larch arabinogalactan for hepatic drug delivery: isolation and characterization of a 9 kDa arabinogalactan fragment. Carbohydr Res 1995;278:113-28
235. Burgalassi S, Nicosia N, Monti D, et al. Larch arabinogalactan for dry eye protection and treatment of corneal lesions: investigation in rabbits. J Ocul Pharmacol Ther 2007;23:541-50
236. Burgalassi S, Nicosia N, Monti D, et al. Arabinogalactan as active compound in the management of corneal wounds: in vitro toxicity and in vivo investigations on rabbits. Curr Eye Res 2011;36:21-8
237. Parmar C, Kaushal MK. Cordia obliqua. In: Wild Fruits. Kalyani Publishers; New Delhi, India: 1982. p. 19-22.Available from: http://www.hort.purdue.edu/newcrop/parmar/05.html. [Last accessed 7 February 2012]
238. Mukherjee B, Dinda SC, Barik BB. Gum cordia: a novel matrix forming material for enteric resistant and sustained drug delivery-A technical note. AAPS PharmSciTech 2008;9:330-3
239. Dinda SC, Mukharjee B. Gum cordia A new tablet binder and emulsifier. Acta Pharm Sci 2009;51:189-98
240. Yadav M, Ahuja M. Preparation and evaluation of nanoparticles of gum cordia, an anionic polysaccharide for ophthalmic delivery. Carbohydr Polym 2010;81:871-7
241. Wang C, Sun J, Luo Y, et al. A polysaccharide isolated from the medicinal herb Bletilla striata induces endothelial cells proliferation and vascular endothelial growth factor expression in vitro. Biotechnol Lett 2006;28:539-43
242. Yuan C, Zhu ZJ. A new adhesive material to gastric mucosa-preparation of Bletilla striata polysaccharide and in vitro and in vivo evaluation of its mucosa adhesion. China papers posted on June 6, 2010. Available from: http://mt.china-papers.com/2/?p=115823 [Last accessed 7 February 2012]
243. Wu XG, Xin M, Chen H, et al. Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis. J Pharm Pharmacol 2010;62:1152-7
244. Kawamura Y. Carob bean gum. Draft prepared for 69th JECFA. Chemical and technical assessment; 2008.p. 1-6. Available from: http://www.fao.org/fileadmin/ templates/agns/pdf/jecfa/cta/69/Carob-bean-gum.pdf [Last accessed 7 February 2012]
245. Lin SL, Pramoda MK. Locust bean gum therapeutic compositions. US4136178; 1979
246. Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 2006;90:819-22 (Pubitemid 43973986)
247. Tung CI, Kottaiyan R, Koh S, et al. Noninvasive, objective, multimodal tear dynamics evaluation of 5 over-the-counter tear drops in a randomized controlled trial. Cornea 2012;31:108-14
248. Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine. J Pharm Sci 1988;77:771-5 (Pubitemid 19030312)
249. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 1998;87:1479-88
250. Abdulrazik M, Behar-Cohen F, Benita S. Drug delivery systems for enhanced ocular absorption. In: Touitou E, Barry BW, editors. Enhancement in drug delivery. 2nd edition. CRC Press; 2007. p. 489-526
251. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 1995;16:61-73
252. Zhang Z, Li G, Shi B. Physicochemical properties of collagen, gelatin and collagen hydrolysate derived from bovine limed split wastes. J Soc Leather Technol Chem 2005;90:23-8
253. Karakelle M, Brunstedt MR. Carrageenan viscoelastics for ocular surgery. US7060297B2; 2006
254. Tammelin T, Paananen A, Osterberg M. Hemicelluloses at interfaces: some aspects of the interactions. In: Rojas OJ, Lucia LA, editors. The nanoscience and technology of renewable biomaterials. 1st edition. Wiley Publishing, Inc; 2009. p. 149-72
255. Rieger MM. Emulsions. In: Lachman L, Lieberman HA, Kanig JL, editors. The theory and practice of industrial pharmacy. 3rd edition. Varghese Publishing House; Bombay, India: 1987. p. 502-33
256. Ahmed I, Patron TF. Importance of the non-corneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 1985;26:584-7 (Pubitemid 15059025)